Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Cellares

Cellares and ProTgen Partner to Automate Manufacturing for ProT-096, a Novel Progenitor T Cell Therapy Designed to Restore Immune Competence

May 11, 2026

From Cellares

Via Business Wire

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

April 28, 2026

From Cellares

Via Business Wire

First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

April 14, 2026

From Cellares

Via Business Wire

Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors

February 18, 2026

From Cellares

Via Business Wire

Cellares to Expand Automated Manufacturing to Gene-Edited Stem Cell Therapies

February 03, 2026

From Cellares

Via Business Wire

Cellares Raises $257 Million Series D Led by BlackRock and Eclipse to Industrialize Global Cell Therapy Manufacturing with Breakthrough Automation

January 28, 2026

From Cellares

Via Business Wire

Cellares Expands Global Smart Factory Network With European Headquarters in the Netherlands

January 12, 2026

From Cellares

Via Business Wire

IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms

January 12, 2026

From Cellares

Via Business Wire

Cellares and City of Hope to Automate Manufacturing of Solid Tumor CAR T Cell Therapy

January 08, 2026

From Cellares

Via Business Wire

Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

December 01, 2025

From Cellares

Via Business Wire

Cellares Appoints Former Kite Global Ops Leader, Christopher McDonald, to Board of Advisors

September 22, 2025

From Cellares

Via Business Wire

Cellares Selects Five Best-in-Class Technology Providers, Tecan, Advanced Instruments, Cytek Biosciences, Slingshot Biosciences and AltemisLab, to Expand Cell Q’s Capabilities in Meeting Demands for Commercial Scale Cell Therapy Quality Control

September 17, 2025

From Cellares

Via Business Wire

Cellares and Mitsui Fudosan Announce the First IDMO Smart Factory for Commercial-Scale Cell Therapy Manufacturing in Japan

May 29, 2025

From Cellares

Via Business Wire

Cellares and University of Wisconsin School of Medicine and Public Health to Automate Clinical-Scale Production of CRISPR-Edited CAR-T for Solid Tumors

April 10, 2025

From Cellares

Via Business Wire

Cellares’ Cell Shuttle™ Receives FDA Advanced Manufacturing Technology (AMT) Designation for Automated Cell Therapy Manufacturing

April 01, 2025

From Cellares

Via Business Wire

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

March 19, 2025

From Cellares

Via Business Wire

Cellares Appoints Ossama Eissa, Former Novartis, Lonza and Legend Biopharma Leader, as Chief Operating Officer

November 12, 2024

From Cellares

Via Business Wire

Cellares and Sony Announce a Joint Development Collaboration to Integrate Flow Cytometry-Based Sorting and Online Analysis into an Automated, High-Throughput Cell Therapy Manufacturing Platform

September 12, 2024

From Cellares

Via Business Wire

Cellares Announces Completion of First cGMP Cell Shuttle at IDMO Smart Factory in Bridgewater, New Jersey

September 05, 2024

From Cellares

Via Business Wire

Cellares Appoints Justin McAnear as CFO and Jonathan Butler as General Counsel

September 03, 2024

From Cellares

Via Business Wire

Cellares Announces Agreement with Kite to Evaluate Its Cell Shuttle Automated Manufacturing Platform

June 27, 2024

From Cellares

Via Business Wire

Cellares Launches Cell Q, the World’s First Automated cGMP QC Workcell for Cell Therapies, to Resolve Manual QC Processing Bottleneck and Extend IDMO Capabilities from Manufacturing Through Quality Control

April 18, 2024

From Cellares

Via Business Wire

Christi Shaw, Former CEO of Kite, a Gilead Company, Appointed to Cellares Advisory Board to Advance Cell Therapy Manufacturing

March 26, 2024

From Cellares

Via Business Wire

Cellares Unveils First cGMP Compliant Cell Shuttle in its South San Francisco Center of Excellence

March 12, 2024

From Cellares

Via Business Wire

Somerset County Welcomes Cellares’ $255M Investment Expected to Create 350 Local Jobs

January 25, 2024

From Cellares

Via Business Wire

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform

November 06, 2023

From Cellares

Via Business Wire

Cellares Announces Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellares’ Technology Adoption Partnership Program

October 11, 2023

From Cellares

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.